Insulin degludec early clinical experience: Does the promise from the clinical trials translate into clinical practice-a case-based evaluation

Journal of Medical Economics

Volumn 18, Issue 2, 2015, Pages 96-105

  Evans, Marc ^a   McEwan, Phil ^b   Foos, Volker ^c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c IQVIA   (United States)

Author keywords

Diabetes treatment; Health economics; Hypoglycemia; Insulin; Insulin degludec

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CASE STUDY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORE DIABETES MODEL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG DOSE INCREASE; DRUG EFFICACY; ECONOMIC ASPECT; ECONOMIC EVALUATION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; ECONOMICS; GLUCOSE BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES;

EID: 84923193619     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.975234     Document Type: Article

References (39)

1. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104-14
2. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50
3. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33:515-21
4. Heise T, Nosek L, Coester H-V, et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012;61(Suppl 1):A259
5. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
6. Bloomgarden ZT, Einhorn D. Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) 2012;3:66
7. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012;15:77-86
8. Brod M, Pohlman B, Wolden M, et al. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res 2013;22:997-1004
9. Fidler C, Elmelund CT, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
10. Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012;96:313-18
11. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013;19:792-9
12. Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
13. Peyrot M, Barnett AH, Meneghini LF, et al. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012;14:1081-7
14. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society. Diabetes Care 2013;36:1384-95
15. Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013;15:546-57
16. Farmer AJ, Brockbank KJ, Keech ML, et al. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med 2012;29:1447-50
17. Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab 2013;16:196-205
18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
19. Erratum in Diabetes Care 2013;36:490
20. Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomised clinical trial. Diabet Med 2013;30:1293-7
21. TM LOW VOLUME trial. Diabetes Care 2013;36:2536-42
22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97
23. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in aflexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-62
24. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013;36:858-64
25. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71
26. Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013;4:605-12
27. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507
28. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175-84
29. Freemantle N, Meneghini L, Christensen T, et al. Insulin degludec improves health-related quality of life (SF-36(R)) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med 2013;30:226-32
30. Freemantle N, Evans M, Christensen T, et al. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:564-71
31. Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-46
32. Palmer AJ, Valentine WJ, Ray JA, et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin 2007;23:895-901
33. Ericsson A, Pollock RF, Hunt B, et al. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16:1442-52
34. Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014; 31: 92-101
35. Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin deglu-dec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin-from the UK health care cost perspective. Diabetes Obes Metab 2014;16:366-75
36. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
37. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20 (1 Suppl):S27-S40
38. Bjorner JB, Lyng WM, Gundgaard J, et al. Benchmarks for interpretation of score differences on the SF-36 health survey for patients with diabetes. Value Health 2013;16:993-1000
39. Philis-Tsimikas A, Del PS, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013;15:760-6